heart-failure
(25)
Selera Medical
Selera Medical is a Y Combinator-backed (W24) medical device startup building MILO - minimally invasive lymphatic offloading - a one-time, catheter-based procedure that treats fluid overload in chronic heart failure. Instead of a lifelong drug regimen, Selera taps the body's lymphatic system to drain trapped fluid from the interstitial space, aiming to break the cycle of repeat hospitalizations that defines late-stage heart failure. Founded in 2023 by CEO Stacie Arechavala and CTO Kevin Bui, both former Stanford Biodesign fellows.
Nuevocor
Nuevocor is a Singapore-founded, clinical-stage biotechnology company developing genetic medicines for cardiomyopathies driven by aberrant mechanobiology - the mechanical stresses that damage heart-muscle cells. Spun out of Singapore's A*STAR research agency in 2021, the company built a proprietary discovery engine called PrOSIA (Protein Organ Specific Interactome Analysis) to map the functional root causes of genetic heart disease. Its lead program, NVC-001, is an AAV-based gene therapy for LMNA-related dilated cardiomyopathy, an aggressive inherited heart condition with no targeted treatment. Nuevocor received FDA IND clearance for NVC-001 in June 2025 and has raised roughly US$80.6 million to date, including a US$45 million Series B in May 2025.
Respiree
Respiree is a Singapore-founded digital health company (an A*STAR spin-off) building clinically validated AI that pairs FDA-cleared cardio-respiratory wearable sensors with software to track lung and heart biomarkers over time. Its 1Bio platform helps hospitals, health systems and biopharma detect patient deterioration - such as COPD flare-ups and heart failure - days in advance, powering remote patient monitoring, clinical decision support and decentralized clinical trials across Asia-Pacific, Australia and the United States.
Us2.ai
Us2.ai is a Singapore-based medtech company that builds FDA-cleared, CE-marked AI software to automate echocardiography (cardiac ultrasound) analysis and reporting. Its vendor-neutral platform - branded the AI Echo Copilot - turns raw DICOM echo studies into fully editable, structured clinical reports in seconds, detecting conditions such as heart failure, aortic stenosis, pulmonary hypertension and cardiac amyloidosis. Founded in 2017 as eko.ai and rebranded to Us2.ai in 2021, the company aims to widen access to expert-level cardiac diagnostics across hospitals, echo labs and clinical-trial core labs worldwide.
Axon Therapies, Inc.
Axon Therapies is a clinical-stage medical device company developing SAVM (Splanchnic Ablation for Volume Management), a minimally invasive, implant-free catheter procedure that ablates the greater splanchnic nerve to calm an overactive sympathetic nervous system and rebalance blood volume in patients with heart failure - particularly heart failure with preserved ejection fraction (HFpEF). Incubated by the medtech studio Coridea and backed by leading healthcare investors, the company is advancing its Satera Ablation System through randomized, sham-controlled feasibility trials.
EBR Systems, Inc.
EBR Systems is a Sunnyvale, California medical device company that developed the WiSE System, the world's first and only leadless left ventricular endocardial pacing device for cardiac resynchronization therapy. About the size of a grain of rice, the ultrasound-powered electrode paces the inside of the heart's left ventricle without wires, working alongside a patient's existing pacemaker or defibrillator. After its pivotal SOLVE-CRT trial was halted early for success, the WiSE System won U.S. FDA approval in April 2025 and began its commercial launch for heart failure patients who have run out of conventional options.
Revamp Medical
Revamp Medical is an Israeli medical device company building the Doraya catheter, a temporary, adjustable flow-reducing catheter for patients hospitalized with acute heart failure. Deployed in the infrarenal inferior vena cava for up to 12 hours, Doraya is designed to relieve venous congestion and improve response to diuretic therapy in patients who respond poorly to standard drugs - addressing the local mechanism of diuretic resistance rather than relying on systemic drugs or dialysis. Founded in 2016 and based in Netanya, the company won FDA Breakthrough Device designation in 2020 and closed a KCK Medtech-led Series A in 2023 to fund U.S. clinical trials.
Shifamed
Shifamed is a Silicon Valley medical technology incubator founded in 2009 by serial entrepreneur Amr Salahieh. It combines human-centered design, in-house engineering, and R&D facilities to build medical device companies from concept to commercial launch, spinning out and incubating startups across cardiovascular, electrophysiology, and ophthalmology. Its portfolio and legacy companies have raised over $800M and produced multiple acquisitions by Boston Scientific, Abbott, Covidien, and Johnson & Johnson.
Zoar Engelman
Zoar Engelman is the co-founder and CEO of Axon Therapies, a clinical-stage medical device company chasing a stubborn problem: heart failure with preserved ejection fraction, a condition that has resisted nearly every drug thrown at it. A biomedical engineer with a PhD from the University of Auckland, Engelman spent two decades turning lab ideas into implantable and catheter-based devices, co-founding roughly nine ventures and helping raise more than $150 million along the way. In September 2025 he stepped up from Chief Scientific Officer to CEO as Axon closed an oversubscribed $32 million Series A to advance SAVM, an implant-free procedure that quiets an overactive sympathetic nervous system to rebalance the body's blood volume.
Fauna Bio
Fauna Bio is an AI-driven drug discovery company that mines roughly 100 million years of evolved disease resistance in mammals to find new human therapies. Founded in 2018 in the San Francisco Bay Area, it combines comparative genomics, a proprietary animal biobank, and machine learning - through its Convergence and Fauna Brain platforms - to translate the biology of hibernators and other resilient species into drug targets for conditions like obesity, heart failure, neurodegeneration, and retinal disease. Its work has attracted a partnership with Eli Lilly worth up to $494 million.
Adona Medical
Adona Medical is a clinical-stage medical device company in Los Gatos, California developing the Delphi System, a chronically adjustable interatrial shunt with integrated bi-atrial pressure monitoring designed to personalize heart failure therapy over time. A Shifamed portfolio company founded in 2019 by Brian Fahey, Amr Salahieh, and Lewis Schwartz, Adona uses shape memory nitinol and an external induction catheter to resize the shunt after implantation without further invasive procedures.
CorVista Health
CorVista Health is a medical technology company applying machine learning to cardiovascular diagnostics. Its FDA-cleared CorVista System is a non-invasive, point-of-care device that captures cardiac and hemodynamic signals and analyzes them in the cloud to assess the likelihood of coronary artery disease and pulmonary hypertension - delivering results in minutes, without radiation, contrast, injections, fasting, or exercise. The company aims to shorten the path from symptoms to diagnosis so patients can be treated earlier.
Cadence
Cadence is a New York-based clinical technology company that helps health systems deliver continuous, proactive care to patients with chronic conditions at home. It pairs FDA-cleared connected devices that track vitals with an AI-powered care platform and a 24/7 clinical team, so doctors can catch problems - rising blood pressure, fluid buildup, glucose swings - before they become emergencies. Cadence partners with more than 20 leading U.S. health systems and supports tens of thousands of patients across dozens of states, targeting chronic diseases such as heart failure, hypertension, type 2 diabetes, and COPD.
Carda Health
Carda Health is a New York-based virtual care company that delivers clinically supervised cardiac and pulmonary rehabilitation into patients' homes. Patients receive a connected care kit and are matched with a clinical exercise physiologist who monitors their vital signs live during sessions. The company exists to fix a brutal gap in heart and lung care: roughly 90% of eligible patients never complete traditional in-person rehab because of transportation, scheduling, and mobility barriers. Carda now treats tens of thousands of patients a year and works with major health plans and health systems.
Cardiosense
Cardiosense is a Chicago-based health-tech company building an AI platform that turns raw physiological signals into clinical intelligence for heart failure. Its FDA-cleared CardioTag wearable simultaneously captures ECG, PPG and seismocardiogram (SCG) signals, and its machine-learning algorithms estimate pulmonary capillary wedge pressure (PCWP) - a key measure of cardiac filling pressure - noninvasively, so clinicians can spot a worsening heart before it lands a patient in the hospital.
HAYA Therapeutics
HAYA Therapeutics is a clinical-stage precision medicines company spun out of Lausanne University Hospital (CHUV) in 2019. It develops RNA-guided programmable therapeutics that target long non-coding RNAs in the so-called 'dark genome' - the roughly 98% of human DNA that does not code for proteins - to reprogram disease-driving cell states. Its lead candidate, HTX-001, is an antisense oligonucleotide targeting the cardiac lncRNA Wisper for heart failure, with a broader pipeline spanning fibrosis, metabolic disease and cancer. The company is headquartered in Lausanne, Switzerland, with US laboratory operations in San Diego, and raised a $65M Series A in May 2025.
Procyrion, Inc.
Procyrion, Inc. is a Houston-based medical device company developing Aortix, a catheter-delivered percutaneous mechanical circulatory support (pMCS) pump. About the width of a pencil, Aortix is anchored in the descending aorta where it unloads the failing heart while boosting blood flow to the kidneys, targeting acute decompensated heart failure and cardiorenal syndrome. The device holds FDA Breakthrough Device Designation and is in the DRAIN-HF pivotal IDE trial after closing a $57.7M Series E in February 2024.
Salubris Biotherapeutics
Salubris Biotherapeutics (SalubrisBio) is a clinical-stage biotechnology company in Gaithersburg, Maryland that engineers complex biologics for diseases with few good options - chiefly heart failure and cancer. Founded in 2016 as the US arm of China's Shenzhen Salubris Pharmaceuticals, its lead candidate JK07 is an antibody-fusion protein designed to harness the regenerative NRG-1/ErbB4 pathway in failing hearts while dialing out the side effects, and its oncology programs JK08 and JK06 pursue solid tumors through immune engagement and a 5T4-targeted biparatopic antibody-drug conjugate.
J. Eduardo Rame
J. Eduardo Rame is a Philadelphia cardiologist who treats the sickest hearts in medicine - patients in the final stage of heart failure who depend on pumps, transplants and the chance their own muscle can be coaxed back to life. As the Louis R. Dinon MD Professor and enterprise chief of Advanced Cardiac and Pulmonary Vascular Disease at Jefferson Health, he runs an integrated division built around recovery rather than replacement. Yale-trained in biophysics, Oxford-trained in health economics and Harvard-trained in medicine, he spent a decade founding Penn's mechanical circulatory support program before bringing that work to Jefferson. His research on left ventricular assist devices, including the landmark MOMENTUM 3 trial, has been cited more than 12,000 times.
Eric Fain
Eric S. Fain, M.D. is the President and CEO of Procyrion, the Houston medical device company building Aortix, a percutaneous micropump roughly the size of a AA battery that is threaded into the aorta to boost blood flow and unload failing hearts. A Stanford-trained physician who never practiced clinically, Fain spent a decade at defibrillator pioneer Ventritex, then two decades climbing to Group President of St. Jude Medical and SVP at Abbott, before returning to startup life in 2018. He closed a $57.7M Series E in 2024 and serves as Lead Independent Director of Orchestra BioMed.
Eric Meizlish
Eric Meizlish is the CEO of Cardiosense, a Chicago digital health company building AI-enabled, non-invasive cardiac monitoring. A Yale-trained investor turned healthcare operator, he co-founded the clinical analytics firm Lumere (sold to GHX), ran the life-sciences procurement platform Prendio-BioProcure, and started his career investing in tech and media at Citadel. He took the Cardiosense top job in September 2025 to scale the company's CardioTag sensor, which predicts pressures and volumes inside the heart without an implant.
Richard Law
Richard Law is the Chief Business Officer of HAYA Therapeutics, the Lausanne- and San Diego-based biotech decoding the 'dark genome' to build RNA-guided medicines that reprogram disease-driving cell states. A computational chemist turned dealmaker with a Oxford PhD in molecular biophysics and an Imperial MBA, he spent over a decade at Evotec, then steered Exscientia through its 2021 Nasdaq IPO, marquee pharma partnerships, and 2024 merger with Recursion before joining HAYA in March 2025 to drive its partnering strategy and growth.
Samuel Murphy
Samuel Murphy is co-founder and CEO of Salubris Biotherapeutics, a clinical-stage biotech in Gaithersburg, Maryland developing complex biologics for cardiovascular, oncology, and neurodegenerative disease. A Penn-trained virologist who did his postdoc in the lab that became Spark Therapeutics, he spent a decade in pharma strategy consulting and life-sciences investment banking before joining Salubris in 2017 and taking the CEO seat in 2020. His lead program, JK07, is the first clinical-stage selective ErbB4 agonist aimed at being a disease-modifying biologic for heart failure. He also runs international business development for the company's Chinese parent, Shenzhen Salubris Pharmaceuticals.
John McCutcheon
John McCutcheon is President, CEO, and Director of EBR Systems, Inc., the Sunnyvale-based medical device company behind the WiSE CRT system - the world's first FDA-approved leadless solution for left ventricular pacing. With over 40 years in medical device sales, marketing, and general management, McCutcheon has shepherded EBR through pivotal clinical trials, FDA Breakthrough Device Designation, and the landmark FDA approval in April 2025. Before EBR, he led Ceterix Orthopaedics to a $105 million acquisition by Smith & Nephew. He brings a track record of building and selling medical device companies, now steering EBR's commercial launch of a technology that could transform how heart failure patients receive cardiac resynchronization therapy.
Brian Fahey
Brian Fahey is a serial medtech entrepreneur who co-founded Adona Medical, a clinical-stage company developing an adjustable interatrial shunt with integrated bi-atrial pressure sensors for heart failure management. A Duke-trained biomedical engineer and Stanford Biodesign alumnus, Fahey previously co-founded Niveus Medical, which delivered over 10,000 ICU rehabilitation treatments before being acquired by Stryker in 2017. At Adona, he guided the company through $95.5M in total funding including a $33.5M Series C in 2024, and oversaw the initiation of first-in-human clinical trials before stepping down as CEO in December 2025.